Head-to-head Superiority to High-dose Dulaglutide: Innovent’s First Piece 3 Clinical Trial of Mazdutide in Chinese language Sufferers with Form 2 Diabetes Met Survey Endpoints, Substitute Info
09 May
Top Stories

Head-to-head Superiority to High-dose Dulaglutide: Innovent’s First Piece 3 Clinical Trial of Mazdutide in Chinese language Sufferers with Form 2 Diabetes Met Survey Endpoints, Substitute Info

Posted by author-avatar
0
Top Stories Tamfitronics SAN FRANCISCO and SUZHOU, China, Would possibly possibly possibly also 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes fine quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other main illnesses, publicizes that the Piece 3 scientific trial (DREAMS-2) of mazdutide (Innovent R&D code: IBI362), a glucagon-enjoy peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese language subjects with model 2 diabetes (T2D) met the principle endpoint. The uncover about results urged that mazdutide became superior when put next with dulaglutide for glycaemic control, and mazdutide furthermore showed a couple of cardiometabolic...
Continue reading